Your browser is no longer supported. Please, upgrade your browser.
Settings
TRPX Therapix Biosciences Ltd. daily Stock Chart
TRPX [NASD]
Therapix Biosciences Ltd.
Index- P/E- EPS (ttm)-2.38 Insider Own2.08% Shs Outstand5.53M Perf Week17.73%
Market Cap14.32M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.46M Perf Month-13.67%
Income-8.50M PEG- EPS next Q- Inst Own1.00% Short Float4.11% Perf Quarter8.37%
Sales- P/S- EPS this Y-12.20% Inst Trans- Short Ratio1.23 Perf Half Y-23.82%
Book/sh0.05 P/B51.80 EPS next Y- ROA-141.70% Target Price18.00 Perf Year-46.71%
Cash/sh0.27 P/C9.55 EPS next 5Y- ROE-220.70% 52W Range2.04 - 9.30 Perf YTD-20.31%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.15% Beta-
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin- 52W Low26.96% ATR0.27
Employees11 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)52.45 Volatility17.77% 10.92%
OptionableNo Debt/Eq5.50 EPS Q/Q-186.70% Profit Margin- Rel Volume0.42 Prev Close2.74
ShortableYes LT Debt/Eq0.00 EarningsOct 21 BMO Payout- Avg Volume115.31K Price2.59
Recom- SMA201.10% SMA502.85% SMA200-18.29% Volume48,264 Change-5.47%
Oct-15-19 08:30AM  Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210 PR Newswire +10.96%
Oct-11-19 08:14AM  The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 06:12PM  Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp. PR Newswire -7.95%
Sep-30-19 07:20PM  Top Marijuana Stocks on the NASDAQ Investopedia -13.82%
Aug-27-19 09:30AM  Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement PR Newswire
Jul-31-19 09:27AM  Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide), a Non-Opiate Based Pain Management Supplement PR Newswire
Jul-23-19 10:25AM  Cannabis M&A: Therapix Biosciences, Destiny Biosciences Plan Stock-For-Stock Deal Benzinga +47.83%
09:30AM  Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a Stock for Stock Transaction Valuing Therapix at US$48 Million PR Newswire
Jul-05-19 03:49AM  Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data PR Newswire
Jun-18-19 09:30AM  Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program PR Newswire -8.36%
May-29-19 09:25AM  Therapix Biosciences Issues Shareholder Update Letter PR Newswire
May-24-19 07:44AM  The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice Benzinga -24.24%
May-23-19 04:30PM  Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance PR Newswire
Mar-28-19 08:36AM  Therapix Biosciences Announces Pricing of $2.25 Million Registered Direct Offering PR Newswire -20.28%
Mar-19-19 06:30AM  Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor PR Newswire
Dec-23-18 07:30AM  Cannabis Stock News Weekend Roundup December 23 Market Exclusive
Dec-21-18 08:30AM  Therapix Biosciences Terminates FSD Acquisition Letter of Intent PR Newswire -22.91%
Dec-11-18 08:30AM  Therapix Biosciences Provides Update Regarding FSD Acquisition PR Newswire -6.42%
Dec-03-18 08:30AM  Therapix Biosciences Reports Third Quarter 2018 Financial Results and Provides Business Update PR Newswire
Nov-29-18 04:34PM  Therapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture PR Newswire
Nov-27-18 08:30AM  Therapix Biosciences Issues $1,500,000 Convertible Debenture PR Newswire -17.22%
Oct-26-18 11:25AM  Treat Aurora Cannabis Stock Normally at Your Own Peril InvestorPlace
Oct-24-18 11:25AM  3 Marijuana Stocks Looking For A New Bull Trend ACCESSWIRE
08:00AM  Todays Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences ACCESSWIRE
06:00AM  Therapix Biosciences Signs Binding LOI to be Acquired by FSD Pharma for $48 Million, to Create Medical Cannabis Industry Innovator PR Newswire
Oct-23-18 08:52AM  Canadian Cannabis Producer To Buy Israeli Medical Cannabis Company Benzinga +22.17%
08:15AM  Stock Market News Daily Roundup October 23 Market Exclusive
03:43AM  Canada's FSD Pharma to buy Israeli medical cannabis firm Therapix Reuters
Oct-22-18 06:56PM  FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a Nasdaq Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments to Create Medical Cannabis Industry Innovator CNW Group
06:49PM  Small medical pot companies plan to merge in $48 million stock deal MarketWatch
Oct-05-18 08:10AM  Therapix Biosciences, Cannabis Based Drug Candidates Pipeline Review ACCESSWIRE
Aug-30-18 01:30PM  Clinical Stage Marijuana Focused Biotech Stocks Trend Higher In August ACCESSWIRE -5.19%
Aug-20-18 08:30AM  Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update PR Newswire
Jul-17-18 08:30AM  Therapix Biosciences Announces Positive Data From Recent Pre-clinical Studies for its Drug Candidate THX-160 for Treatment of Pain PR Newswire +11.29%
Jul-12-18 08:30AM  Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain Cannabinoid-Based Drug Pipeline Assets to Cure Pharmaceutical PR Newswire -9.87%
Jul-11-18 08:57AM  Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd. GlobeNewswire
Jun-27-18 08:00AM  Therapix Biosciences Updates Regarding TASE Delisting PR Newswire -7.88%
Jun-11-18 04:00PM  Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome PR Newswire
Jun-05-18 04:30PM  Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug PR Newswire -5.07%
May-31-18 04:55PM  Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update PR Newswire
May-15-18 08:31AM  Therapix Biosciences Issues CEO's Letter to Shareholders PR Newswire
May-09-18 08:35AM  Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange PR Newswire
Apr-11-18 08:00AM  InMed Announces Appointment of Joshua Blacher as Chief Business Officer CNW Group -5.63%
07:40AM  Blog Exposure - Therapix Reported Positive Top-line Results of Phase-IIa Study for Tourette Syndrome Treatment ACCESSWIRE
Apr-10-18 08:20AM  Todays Research Reports on Stocks to Watch: Teva and Therapix ACCESSWIRE -11.31%
Apr-09-18 07:18AM  Therapix shares surge 30% premarket on news of positive trial of Tourette syndrome treatment MarketWatch +15.58%
07:05AM  Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program PR Newswire
Mar-20-18 08:50AM  Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain PR Newswire
Feb-07-18 08:30AM  Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected PR Newswire
Jan-09-18 08:30AM  Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase 2018 PR Newswire
Dec-04-17 08:38AM  Therapix expects to have results of Tourette's drug trial by end of Q1 Reuters
08:30AM  Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program PR Newswire
Nov-21-17 08:30AM  Therapix Biosciences Spotlighted in Financial and Trade Media Outlets PR Newswire
Nov-10-17 08:30AM  Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids PR Newswire
Nov-09-17 08:00AM  Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update PR Newswire
Nov-07-17 09:00AM  Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders GlobeNewswire
08:30AM  Therapix to Present at and Attend Investor Conferences in London PR Newswire
Nov-02-17 02:30PM  Therapix Biosciences Third Quarter 2017 Conference Call and Webcast Scheduled for Thursday, November 9, 2017 PR Newswire
08:30AM  Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer PR Newswire
Oct-30-17 10:41AM  Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd PR Newswire
10:41AM  Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd CNW Group
08:30AM  Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center PR Newswire
Oct-18-17 08:30AM  Therapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea PR Newswire
Oct-09-17 08:10AM  Today's Research Reports on Stocks to Watch: Omeros Corporation and Therapix Biosciences ACCESSWIRE
Oct-06-17 08:30AM  Therapix Signs Formulation Development and Clinical Manufacturing Agreement with Catalent for THX-TS01 PR Newswire
Sep-28-17 08:20AM  Today's Research Reports on Stocks to Watch: Therapix Biosciences and Immune Pharmaceuticals ACCESSWIRE
Sep-27-17 08:41AM  Therapix Biosciences shares surge 6% on preclinical results for cognitive impairment therapy MarketWatch
08:30AM  Therapix's First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study PR Newswire
Aug-10-17 08:00AM  Therapix Biosciences Reports Second Quarter 2017 Financial Results and Provides Business Update PR Newswire
Aug-03-17 08:30AM  Therapix Biosciences Second Quarter 2017 Conference Call and Webcast Scheduled for Thursday, August 10, 2017 PR Newswire
Jul-11-17 09:00AM  CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israels Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids GlobeNewswire
08:00AM  CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel's Assuta Medical Center to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids PR Newswire
Jun-27-17 04:15PM  Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28 PR Newswire
10:00AM  Therapix Biosciences Ltd. (Nasdaq: TRPX) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
May-30-17 08:15AM  Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June PR Newswire
May-24-17 05:40PM  Therapix Biosciences Announces CEO Change PR Newswire
04:05PM  Therapix Biosciences Announces CEO Change PR Newswire
May-08-17 08:30AM  Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome PR Newswire
May-03-17 08:30AM  Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer PR Newswire
Apr-05-17 08:55AM  Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology PR Newswire
08:55AM  Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology
Apr-04-17 07:05AM  Fresh Off IPO, Therapix Biosciences Already Aiming at Tourettes Phase 3 Trial 24/7 Wall St.
07:05AM  Fresh Off IPO, Therapix Biosciences Already Aiming at Tourettes Phase 3 Trial
Apr-03-17 04:01PM  Therapix Biosciences Ltd. Announces Full Exercise of Underwriters' Over-Allotment Option PR Newswire
Mar-27-17 04:43PM  Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS PR Newswire
Mar-25-17 01:04PM  THERAPIX BIOSCIENCES LTD. Financials
Mar-24-17 09:30AM  Cancer Genetics and Therapix Biosciences Get Financial Boost Accesswire
Mar-22-17 04:07PM  Cannabis Space Continues To Shine As Latest IPO Therapix BioSciences (TRPX) Oversubscribed Insider Monkey
04:07PM  Cannabis Space Continues To Shine As Latest IPO Therapix BioSciences (TRPX) Oversubscribed at Insider Monkey
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.